UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16
OR 15d-16 UNDER
THE SECURITIES EXCHANGE
ACT OF 1934
For the month of June 2024
Commission File Number:
001-40540
Atour Lifestyle Holdings
Limited
(Exact name of registrant
as specified in its charter)
1st floor, Wuzhong Building,
618 Wuzhong Road, Minhang
District,
Shanghai, People’s
Republic of China
(+86) 021-64059928
(Address of principal
executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
EXPLANATORY NOTE
Exhibits 1.1 and 5.1 to this current report on Form 6-K are incorporated by reference into the registration statement on Form F-3 of Atour
Lifestyle Holdings Limited (File No. 333-275880) and shall be a part thereof from the date on which this current report is furnished,
to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Atour Lifestyle Holdings Limited |
| |
|
| |
By: |
/s/ HAIJUN WANG |
| |
|
Name: |
Haijun Wang |
| |
|
Title: |
Chairman of the Board of Director and Chief Executive Officer |
| |
|
| Date: June 12, 2024 |
Exhibit 1.1
10,000,000
American Depositary Shares
Representing
30,000,000 Class A Ordinary Shares
(par value US$0.0001 per share)
Atour Lifestyle Holdings Limited
UNDERWRITING AGREEMENT
June 11, 2024
BofA Securities, Inc.
One Bryant Park
New York, NY 10036
United States of America
CMB International Capital Limited
45/F, Champion Tower
3 Garden Road
Central
Hong Kong
Citigroup Global Markets Inc.
388 Greenwich Street
New York, NY 10013
United States of America
As representatives (the “Representatives”) of the
several Underwriters named in Schedule I hereto
Ladies and Gentlemen:
The shareholders named in Schedule II hereto (the
“Selling Shareholders”) of Atour Lifestyle Holdings Limited, an exempted company incorporated in the Cayman Islands
(the “Company”), severally propose to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”)
an aggregate of 10,000,000 American Depositary Shares representing 30,000,000 Class A ordinary shares, par value US$0.0001
per share, of the Company (the “Firm ADSs”).
The Selling Shareholders also propose to sell
to the several Underwriters not more than an additional 1,500,000 American Depositary Shares representing 4,500,000 Class A
ordinary shares, par value US$0.0001 per share, of the Company (the “Additional ADSs”) if and to the extent that the
Representatives, as managers of the offering, shall have determined to exercise, on behalf of the Underwriters, the right to purchase
such American Depositary Shares granted to the Underwriters in Section 3 hereof. The Firm ADSs and the Additional ADSs are hereinafter
collectively referred to as the “ADSs.” The Class A ordinary shares, par value US$0.0001 per share, and the Class B
ordinary shares, par value US$0.001 per share, of the Company are hereinafter referred to as the “Ordinary Shares.”
The
ADSs are to be issued pursuant to a deposit agreement (the “Deposit Agreement”), dated as of November 10,
2022, among the Company, The Bank of New York Mellon, as depositary (the “Depositary”), and holders from time to time
of the American Depositary Receipts (the “ADRs”) issued by the Depositary and evidencing the ADSs. The ADSs will represent
the right to receive the Ordinary Shares deposited pursuant to the Deposit Agreement.
The
Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form F-3
(File No. 333-275880), including a prospectus, relating to the securities (the “Shelf Securities”), including
the Ordinary Shares represented by the ADSs, to be issued from time to time by the Company and/or to be sold by the Company’s selling
shareholder(s) from time to time, as the case may be. The registration statement as amended to the date of this Agreement, including
the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A or Rule 430B
under the Securities Act of 1933, as amended (the “Securities Act”), is hereinafter referred to as the “Registration
Statement”; the related prospectus covering the Shelf Securities dated December 4, 2023 is hereinafter referred to as the
“Base Prospectus.” The Base Prospectus, as supplemented by the prospectus supplement specifically relating to the Ordinary
Shares represented by the ADSs in the form first used to confirm sales of the ADSs (or in the form first made available to the Underwriters
by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the “Prospectus.”
The Company has filed a registration statement on Form F-6 relating to the ADSs with the Commission (such registration statement
on Form F-6, including all exhibits thereto, as amended at the time such registration statement becomes effective, being hereafter
referred to as the “ADS Registration Statement”). The Company has also filed, in accordance with Section 12 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), a registration statement on Form 8-A (the
“Form 8-A Registration Statement”) to register the Class A ordinary shares, par value US$0.0001 per share,
of the Company under Section 12(b) of the Exchange Act.
For
purposes of this Agreement, “free writing prospectus” has the meaning set forth in Rule 405 under the Securities
Act, “preliminary prospectus” means the preliminary prospectus supplement specifically related to the Ordinary
Shares represented by the ADSs dated June 10, 2024 (including the Base Prospectus), “Time of Sale Prospectus”
means the preliminary prospectus together with the documents and pricing information set forth in Schedule III hereto, and “broadly
available road show” means a “bona fide electronic road show” as defined in Rule 433(h)(5) under the
Securities Act that has been made available without restriction to any person. As used herein, the terms “Registration Statement,”
“Base Prospectus”, “preliminary prospectus,” “Time of Sale Prospectus” and “Prospectus”
shall include the documents, if any, incorporated by reference therein as of the date hereof. The terms “supplement,” “amendment,”
and “amend” as used herein with respect to the Registration Statement, the Base Prospectus, the Time of Sale Prospectus,
or the Prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Exchange Act that
are deemed to be incorporated by reference therein.
1. Representations
and Warranties of the Company. The Company represents and warrants to and agrees with each of
the Underwriters that:
(a) Each
of the Registration Statement, ADS Registration Statement and the Form 8-A Registration Statement has become effective; no stop order
suspending the effectiveness of the Registration Statement, the ADS Registration Statement or the Form 8-A Registration Statement
is in effect, and no proceedings for such purpose are pending before or, to the Company’s knowledge, threatened by the Commission.
If the Registration Statement is an automatic shelf registration statement as defined in Rule 405 under the Securities Act, the Company
is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act) eligible to use the Registration Statement as an
automatic shelf registration statement and the Company has not received notice that the Commission objects to the use of the Registration
Statement as an automatic shelf registration statement.
(b) (i) Each
document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus or the
Prospectus, including, but not limited to, the Company’s Annual Report on Form 20-F for the fiscal year ended December 31,
2023 filed with the Commission pursuant to the Exchange Act on April 26, 2024 (the “Annual Report”), complied
or will comply when so filed in all material respects with the Exchange Act and the rules and regulations of the Commission thereunder,
(ii) each of the Registration Statement, the ADS Registration Statement and the Form 8-A Registration Statement, when it became
effective, did not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii) each
of the Registration Statement, the ADS Registration Statement and the Prospectus complies and, as amended or supplemented, if applicable,
will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder,
(iv) the Form 8-A Registration Statement complies and, as amended or supplemented, if applicable, will comply in all material
respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (v) the Time of Sale
Prospectus does not, and at the time of each sale of the ADSs in connection with the offering when the Prospectus is not yet available
to prospective purchasers and at the Closing Date (as defined in Section 5) and at each Option Closing Date (as defined in Section 3),
the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading, (vi) each broadly available road show, if any, when considered together with the Time of Sale Prospectus,
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading and (vii) the Prospectus does not contain and, as amended
or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations
and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus
or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through
the Representatives expressly for use therein, it being understood and agreed that the only such information is that described in Section 11(c).
(c) The
Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities
Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been,
or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations
of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Any such
free writing prospectus, as of its issue date and at all subsequent times through the completion of the sale of the ADSs, did not, does
not and will not include any information that conflicted, conflicts or will conflict with the information then contained in the Registration
Statement, the Time of Sale Prospectus or any preliminary or other prospectus deemed to part thereof that has not been superseded or modified.
Except for the free writing prospectuses, if any, identified in Schedule III hereto, and broadly available road shows, if any, each furnished
to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior consent of
the Representatives, prepare, use or refer to, any free writing prospectus.
(d) The
Company has been duly incorporated, is validly existing as an exempted company with limited liability in good standing under the laws
of the Cayman Islands, has the corporate power and authority to own its property and to conduct its business as described in the Time
of Sale Prospectus and is duly qualified to transact business and is in good standing (or the foreign equivalent to the extent the concept
is applicable in such jurisdiction) in each jurisdiction in which the conduct of its business or its ownership or leasing of property
requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material
adverse effect on the condition (financial or otherwise), earnings, results of operations, business or prospects of the Company and its
Subsidiaries (as defined below), taken as a whole, or on the ability of the Company to carry out its obligations under this Agreement
and the Deposit Agreement (a “Material Adverse Effect”). The currently effective memorandum and articles of association
or other constitutive or organizational documents of the Company comply with the requirements of applicable Cayman Islands law and are
in full force and effect.
(e) Each
of the Company’s direct and indirect subsidiaries has been identified on Schedule V hereto (the “Subsidiaries”).
Each of the Subsidiaries has been duly incorporated, is validly existing as a corporation or organization in good standing under the laws
of the jurisdiction of its incorporation or organization, has the corporate power and authority to own its property and to conduct its
business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction
in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the
failure to be so qualified or be in good standing would not have a Material Adverse Effect; all of the equity interests of each Subsidiary
have been duly and validly authorized and issued, are duly paid (to the extend they have become due and payable) in accordance with its
respective articles of association in effect as of the date hereof, and non-assessable and are free and clear of all liens, encumbrances,
equities or claims, and are owned as described in the Time of Sale Prospectus. None of the outstanding share capital or equity interest
in any Subsidiary was issued in violation of preemptive or similar rights of any security holder of such Subsidiary. All of the constitutive
or organizational documents of each of the Subsidiaries comply with the requirements of applicable laws of its jurisdiction of incorporation
or organization and are in full force and effect.
(f) Except
as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i) none of the Company nor any
of its Subsidiaries is currently prohibited, directly or indirectly, from (1) paying any dividends or making any other distributions
on its share capital, (2) making or repaying any loan or advance to the Company or any other Subsidiary or (3) transferring
any of its properties or assets to the Company or any other Subsidiary; and (ii) all dividends and other distributions declared and
payable upon the share capital of the Company or any of its Subsidiaries (1) may be converted into foreign currency that may be freely
transferred out of such entity’s jurisdiction of incorporation, without the consent, approval, authorization or order of, or qualification
with, any court or governmental agency or body in such entity’s jurisdiction of incorporation or tax residence; and (2) are
not and will not be subject to withholding, value added or other taxes under the currently effective laws and regulations of such entity’s
jurisdiction of incorporation, without the necessity of obtaining any consents, approvals, authorizations, orders, registrations, clearances
or qualifications of or with any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body
or agency having jurisdiction over the Company, any of the Subsidiaries or any of their respective properties, assets or operations (each,
a “Governmental Entity”).
(g) The
Company possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the Subsidiaries,
through its rights to authorize the shareholders of the Subsidiaries to exercise their voting rights.
(h) The
ADSs have been approved for listing on the Nasdaq Global Select Market.
(i) This
Agreement has been duly authorized, executed and delivered by the Company.
(j) The
Deposit Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery
by the Depositary, constitutes a valid and legally binding agreement of the Company, enforceable in accordance with its terms, subject,
as to enforceability, to bankruptcy, insolvency, reorganization and similar laws of general applicability relating to or affecting creditors’
rights and to general equity principles, and upon issuance by the Depositary of ADRs evidencing ADSs and the deposit of Ordinary Shares
in respect thereof in accordance with the provisions of the Deposit Agreement, such ADRs will be duly and validly issued and the persons
in whose names the ADRs are registered will be entitled to the rights specified therein and in the Deposit Agreement; and the Deposit
Agreement and the ADRs conform in all material respects to the descriptions thereof contained in each of the Time of Sale Prospectus and
the Prospectus.
(k) The
authorized share capital of the Company conforms as to legal matters to the description thereof contained in each of the Time of Sale
Prospectus and the Prospectus.
(l) The
Ordinary Shares outstanding have been duly authorized and validly issued, and are fully paid and non-assessable.
(m) The
Ordinary Shares represented by the ADSs to be sold by the Selling Shareholders have been duly authorized and validly issued and are fully
paid and non-assessable. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, no person
has the right, contractual or otherwise, to cause the Company to issue or sell to it any Ordinary Shares, ADSs or any other share capital
of or other equity interests in the Company.
(n) Neither
the Company nor any of its Subsidiaries is (i) except as disclosed in each of the Registration Statement, the Time of Sale Prospectus
and the Prospectus, in breach of or in default under any laws, regulations, rules, orders, decrees, guidelines or notices of its jurisdiction
of organization or any other jurisdiction where it operates, (ii) in violation of its constitutive or organizational documents, or
(iii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties
may be bound, except in the case of (i) and (iii) above, where any such breach or default would not, individually or in aggregate,
have a Material Adverse Effect.
(o) The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement and the Deposit
Agreement will not contravene (i) any provision of applicable law or the memorandum and articles of association of the Company, (ii) any
agreement or other instrument binding upon the Company or any of its Subsidiaries that is material to the Company and its Subsidiaries,
taken as a whole, or (iii) any judgment, order or decree of any Governmental Entity having jurisdiction over the Company or any Subsidiary;
and no consent, approval, authorization or order of, or qualification with, any Governmental Entity is required for the performance by
the Company of its obligations under this Agreement and the Deposit Agreement, except such as may be required by the securities or Blue
Sky laws of the various states of the United States in connection with the offer and sale of the ADSs.
(p) There
has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial
or otherwise, or in the earnings, business or operations of the Company and its Subsidiaries, taken as a whole, from that set forth in
the Time of Sale Prospectus.
(q) There
are no legal or governmental proceedings pending or threatened to which the Company or any of its Subsidiaries is a party or to which
any of the properties of the Company or any of its Subsidiaries is subject (i) other than proceedings accurately described in all
material respects in the Time of Sale Prospectus and proceedings that would not have a Material Adverse Effect or (ii) that are required
to be described in the Registration Statement or the Prospectus and are not so described; and there are no statutes, regulations, contracts
or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the
Registration Statement that are not described or filed as required.
(r) The
preliminary prospectus filed pursuant to Rule 424 under the Securities Act complied when so filed in all material respects with the
Securities Act and the applicable rules and regulations of the Commission thereunder.
(s) The
Company is not required to register as an “investment company” as such term is defined in the Investment Company Act of 1940,
as amended.
(t) Except
as disclosed in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company and its Subsidiaries (i) are
in compliance with any and all applicable national, provincial and local laws and regulations relating to the protection of human health
and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”),
(ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where
such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with
the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a Material Adverse Effect.
(u) Except
as disclosed in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no costs or liabilities
associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure
of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities
and any potential liabilities to third parties) which would, singly or in the aggregate, have a Material Adverse Effect.
(v) Except
as disclosed in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no contracts, agreements
or understandings between the Company and any person granting such person the right to require the Company to file a registration statement
under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Ordinary
Shares registered pursuant to the Registration Statement.
(w) (i) None
of the Company or its Subsidiaries, or any director or officer thereof, or, to the Company’s knowledge, any employee, agent or representative
thereof or their respective affiliates, is aware of or has taken or will take any action, directly or indirectly, that would result in
a violation by such persons of the Foreign Corrupt Practice Act of 1977, as amended, and the rules of regulations thereunder, the
U.K. Bribery Act 2010, as amended, and the rules and regulations thereunder, or any other applicable anti-corruption law in furtherance
of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything
else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of
the foregoing, or any political party or party official or candidate for political office) (“Government Official”)
in order to influence official action, or to any person in violation of any applicable anti-corruption laws; and (ii) the Company
and its Subsidiaries and its and their affiliates have conducted their businesses in compliance with applicable anti-corruption laws and
have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance
with such laws and with the representations and warranties contained herein.
(x) The
operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with all applicable financial recordkeeping
and reporting requirements, including, to the extent applicable, those of the Bank Secrecy Act, as amended by Title III of the Uniting
and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act) and
the applicable anti-money laundering statutes of jurisdictions where the Company and its Subsidiaries conduct business, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
or regulatory agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before
any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
(y) (i) None
of the Company, any of its Subsidiaries, or any director, officer thereof, or, to the Company’s knowledge, any employee, agent,
affiliate or representative of the Company or any of its Subsidiaries, is an individual or entity (“Person”) that is,
or is owned or controlled by one or more Persons that are:
(A) the
subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”),
the U.S. Department of State, the United Nations Security Council (“UNSC”), the European Union (“EU”)
(including under Council Regulation (EC) No. 194/2008), Her Majesty’s Treasury (“HMT”), the State Secretariat
for Economic Affairs, or other relevant sanctions authority (collectively, “Sanctions”), or engaged in any activities
sanctionable under the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010, the Iran Sanctions Act, the Iran Threat
Reduction and Syria Human Rights Act, or any applicable executive order, or
(B) located,
organized or resident in a country, region or territory that is, or whose government is, the subject or the target of Sanctions (including,
without limitation, the Crimea region of Ukraine, the so-called Donetsk People’s Republic, the so-called Luhansk People’s
Republic, Cuba, Iran, North Korea and Syria) (each a “Sanctioned Country”).
(ii) For
the past 5 years, the Company and its Subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage
in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or
was the subject of Sanctions.
(z) Subsequent
to the respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus,
(i) the Company and its Subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into
any material transaction; (ii) the Company has not purchased any of its outstanding share capital, nor declared, paid or otherwise
made any dividend or distribution of any kind on its share capital other than ordinary and customary dividends; and (iii) there has
not been any material change in the share capital, short-term debt or long-term debt of the Company and its Subsidiaries, except in each
case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus.
(aa) The
Company and its Subsidiaries have good and marketable title (in fee simple in the case of real property in applicable jurisdictions, and
valid land use rights and building ownership certificates in the case of real property in the PRC) to all real property and good and marketable
title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case free
and clear of all liens, encumbrances and defects except such as are described in each of the Registration Statement, the Time of Sale
Prospectus and the Prospectus or such as do not materially affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company and its Subsidiaries; and any real property and buildings held under lease by the
Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material
and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries, except
in each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus.
(bb) Except
as disclosed in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company and its Subsidiaries own,
possess, or have been authorized to use, or can acquire on reasonable terms sufficient trademarks, trade names, patent rights, copyrights,
domain names, licenses, trade secrets, inventions, technology, know-how and other intellectual property and similar rights, including
registrations and applications for registration thereof (collectively, “Intellectual Property Rights”) necessary or
material to the conduct of the business as now conducted, and the expected expiration of any such Intellectual Property Rights would not,
individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in each of the Registration Statement, the Time
of Sale Prospectus and the Prospectus, to the knowledge of the Company, (i) there is no material infringement, misappropriation,
breach, default or other violation, or the occurrence of any event that with notice or the passage of time would constitute any of the
foregoing, by any third parties of any of the Intellectual Property Rights of the Company or its Subsidiaries; (ii) there is no pending
or threatened action, suit, proceeding or claim by others challenging the Company’s or the subsidiaries’ or Subsidiaries’
rights in or to, or the violation of any of the terms of, any of their Intellectual Property Rights, and the Company is unaware of any
facts which would form a reasonable basis for any such claim; and (iii) there is no pending or threatened action, suit, proceeding
or claim by others that the Company or any of its Subsidiaries infringes, misappropriates or otherwise violates or conflicts with any
Intellectual Property Rights or other proprietary rights of others and the Company is unaware of any other fact which would form a reasonable
basis for any such claim, except in each case covered by clauses (i) to (iii) such as would not, if determined adversely to
the Company or its Subsidiaries, individually or in the aggregate, have a Material Adverse Effect.
(cc) The
Company has adopted and maintains data privacy and security policies designed to comply with applicable laws, and each of the Company
and the Subsidiaries has complied with these policies and third-party obligations (imposed by applicable laws, regulations or contracts)
regarding the collection, use, transfer, storage, protection, disposal and disclosure by the Company and the Subsidiaries of personally
identifiable information and any other information collected from or provided by third parties in all material respects. The Company and
the Subsidiaries have taken commercially reasonable steps to protect the information technology systems and data used in connection with
the operation of the Company and the Subsidiaries. There has been no material security breach or attack or other compromise of or relating
to any such information technology systems or data, and, except as disclosed in each of the Registration Statement, the Time of Sale Prospectus
and the Prospectus, no material action, suit or proceeding (including, without limitation, governmental investigations or inquiries) by
or before any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company or any of the Subsidiaries
with respect to applicable data privacy and security laws is pending or threatened.
(dd) No
material labor dispute with the employees of the Company or any of its Subsidiaries exists, except as described in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus, or, to the knowledge of the Company, is imminent; and the Company is not aware
of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors
that could have a Material Adverse Effect.
(ee) Neither
the Company nor any of its Subsidiaries has sent or received any written communication regarding termination of, or intent not to renew,
any of contracts or agreements specifically referred to or described in the Time of Sale Prospectus, or specifically referred to or described
in, or filed as an exhibit to, the Registration Statement, and no such termination or non-renewal has been threatened by the Company,
any of its Subsidiaries or, to the Company’s knowledge after due inquiry, any other party to any such contract or agreement, except
for such terminations and non-renewals that would not, individually or in the aggregate, result in a Material Adverse Effect.
(ff) The
Company and each of its subsidiaries engaged in the business of hotel operation and management (“Hotel Subsidiaries”)
are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary
in the businesses in which they are engaged; neither the Company nor any of its Hotel Subsidiaries has been refused any insurance coverage
sought or applied for; and neither the Company nor any of its Hotel Subsidiaries has any reason to believe that it will not be able to
renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business at a cost that would not have a Material Adverse Effect, except in each case as described in each of
the Registration Statement, the Time of Sale Prospectus and the Prospectus.
(gg) The
Company and its Subsidiaries possess all licenses, consents, authorizations, approvals, orders, certificates and permits issued by the
appropriate national, provincial or local regulatory authorities (including, for the avoidance of doubt, all such authorities in the PRC)
necessary to conduct their respective businesses; neither the Company nor any of its Subsidiaries has received any notice of proceedings
relating to the revocation or modification of any such license, consent, authorization, approval, order, certificate or permit which,
singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, except
as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus; and the Company and its Subsidiaries
are in compliance with the provisions of all such licenses, consents, authorizations, approvals, orders, certificates or permits in all
material respects.
(hh) The
Company maintains effective internal control over financial reporting (as defined under Rule 13-a15 and Rule 15d-15 under the
Exchange Act) and a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed
in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with generally accepted accounting principles in the United States and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. Except as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, since the
end of the Company’s most recent audited fiscal year, there has been (i) no material weakness in the Company’s internal
control over financial reporting (whether or not remediated) and (ii) no change in the Company’s internal control over financial
reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
reporting. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange
Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that
material information relating to the Company and its Subsidiaries is made known to the Company’s principal executive officer and
principal financial officer by others within those entities; and such disclosure controls and procedures are effective.
(ii) There
is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such,
to comply with any applicable provision of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”).
(jj) KPMG
Huazhen LLP, who have certified certain financial statements of the Company, are independent public accountants as required by the Securities
Act and the rules and regulations of the Commission thereunder and are independent in accordance with the requirements of the U.S.
Public Company Accounting Oversight Board.
(kk) The
audited consolidated financial statements (and the notes thereto) of the Company included in the Registration Statement, Time of Sale
Prospectus and Prospectus fairly present in all material respects the consolidated financial position of the Company as of the dates specified
and the consolidated results of operations and changes in the consolidated financial position of the Company for the periods specified,
and such financial statements have been prepared in conformity with US GAAP applied on a consistent basis throughout the periods presented
(other than as described therein); the summary and selected consolidated financial data included in the Registration Statement, Time of
Sale Prospectus and Prospectus present fairly the information shown therein and have been compiled on a basis consistent with that of
the audited consolidated financial statements included therein; the interactive data in eXtensible Business Reporting Language included
in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance
with the Commission’s rules and guidelines applicable thereto. The Company is not reviewing or investigating, and neither the
Company’s independent auditors nor its internal auditors have recommended that the Company review or investigate, (i) adding
to, deleting, changing the application of, or changing the Company’s disclosure with respect to, any of the Company’s material
accounting policies, (ii) any matter that could result in a restatement of the Company’s financial statements for any annual
or interim period during the current or prior two fiscal years, or (iii) any significant deficiency, change in internal controls
or fraud involving management or other employees who have a significant role in internal controls.
(ll) The
section entitled “Item 5.E. Critical Accounting Estimates” in the Annual Report accurately describes: (i) accounting
policies which the Company believes are the most important in the portrayal of the Company’s financial condition and results of
operations and which require management’s most difficult, subjective or complex judgments (“Critical Accounting Policies”);
(ii) judgments and uncertainties affecting the application of Critical Accounting Policies; and (iii) the likelihood that materially
different amounts would be reported under different conditions or using different assumptions; and the Company’s Board of Directors
and management have reviewed and agreed with the selection, application and disclosure of the Critical Accounting Policies and have consulted
with independent public accountants with regard to such disclosure.
(mm) The
sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in
the Time of Sale Prospectus and the Prospectus and “Item 5. Operating and Financial Review and Prospects” in the Annual Report
accurately and fully describe: (i) all material trends, demands, commitments, events, uncertainties and risks, and the potential
effects thereof, that the Company believes would materially affect liquidity and are reasonably likely to occur; and (ii) all off-balance
sheet transactions, arrangements, and obligations, including, without limitation, relationships with unconsolidated entities that are
contractually limited to narrow activities that facilitate the transfer of or access to assets by the Company or any of its Subsidiaries,
such as structured finance entities and special purpose entities (collectively, “off-balance sheet arrangements”) that are
reasonably likely to have a material effect on the liquidity of the Company or any of its Subsidiaries or the availability thereof or
the requirements of the Company or any of its Subsidiaries for capital resources.
(nn) The
statements in the Time of Sale Prospectus and the Prospectus under the headings “Summary,” “Risk Factors,” “Use
of Proceeds”, “Dividend Policy,” “Enforceability of Civil Liabilities,” “Description of Share Capital,”
“Description of American Depositary Shares,” “Management,” “Taxation,” “Underwriting,”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in the Annual Report
under the headings “Item 4.B. Business Overview,” “Item 5. Operating and Financial Review and Prospects” and “Item
7.B. Related Party Transactions” insofar as such statements summarize legal matters, agreements, documents or proceedings discussed
therein, are accurate, complete and fair summaries of such matters described therein in all material respects.
(oo) Any
statistical and market-related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on
or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent required,
the Company has obtained the written consent to the use of such data from such sources.
(pp) Except
as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company has not sold, issued or
distributed any Ordinary Shares during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A
under, or Regulation D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified share
option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants.
(qq) Neither
the Company nor any of its Subsidiaries has taken, directly or indirectly, any action which was designed to or which has constituted or
which might reasonably be expected to cause or result in stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the ADSs.
(rr) The
Company and each of its Subsidiaries have filed all national, provincial, local and foreign tax returns required to be filed through the
date of this Agreement or have requested extensions thereof (except where the failure to file would not, individually or in the aggregate,
have a Material Adverse Effect) and have paid all taxes required to be paid thereon (except for cases in which the failure to file or
pay would not have a Material Adverse Effect, or, except as currently being contested in good faith and for which reserves required by
U.S. GAAP have been created in the financial statements of the Company), and no tax deficiency has been determined adversely to the Company
or any of its Subsidiaries which has had (nor does the Company nor any of its Subsidiaries have any notice or knowledge of any tax deficiency
which could reasonably be expected to be determined adversely to the Company or its Subsidiaries and which could reasonably be expected
to have) a Material Adverse Effect.
(ss) The
Company (i) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent
of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities
Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii) has not authorized
anyone other than the Underwriters to engage in Testing-the-Waters Communications. The Company reconfirms that the Representatives have
been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters
Communications other than those listed on Schedule IV hereto. “Testing-the-Waters Communication” means any oral or written
communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act. “Written Testing-the-Waters
Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under
the Securities Act.
(tt) As
of the time of each sale of ADSs in connection with the offering when the Prospectus is not yet available to prospective purchasers, no
individual Written Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included, includes or
will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading.
(uu) The
Company has not distributed and, prior to the later of the Closing Date or any Option Closing Date and the completion of the distribution
of the ADSs will not distribute any offering material in connection with the offering and sale of the ADSs other than the preliminary
prospectus, the Prospectus, any free writing prospectuses, if any, identified in Schedule III hereto.
(vv) Except
as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, none of the Company or any of its
Subsidiaries is engaged in any material transactions with its directors, officers, management, shareholders, or any other affiliate, including
any person who formerly held a position as a director, officer and/or shareholder.
(ww) There
are no contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company
or any Underwriter for a brokerage commission, finder’s fee or other similar payment in connection with the issuance and sale of
the ADSs and the Ordinary Shares represented thereby.
(xx) The
Company is aware of and has been advised as to, the content of the Rules on Mergers and Acquisitions of Domestic Enterprises by
Foreign Investors jointly promulgated by the Ministry of Commerce, the State Assets Supervision and Administration Commission, the
State Tax Administration, the State Administration of Industry and Commerce, the China Securities Regulatory Commission (“CSRC”)
and the State Administration of Foreign Exchange of the PRC on August 8, 2006, as amended on June 22, 2009 (together with any
official clarification, guidance, interpretation or implementation rules related thereto, the “M&A Rules”),
in particular the relevant provisions thereof which purport to require offshore special purpose vehicles, or SPVs, formed for listing
purposes and controlled directly or indirectly by PRC companies or individuals, to obtain the approval of the CSRC prior to the listing
and trading of their securities on an stock exchange located outside PRC; the Company has received legal advice specifically with respect
to the M&A Rules from its PRC counsel and the Company understands such legal advice; and the Company has fully communicated such
legal advice from its PRC counsel to each of its directors that signed the Registration Statement and each director has confirmed that
he or she understands such legal advice; the Company and each director of the Company that signed the Registration Statement understand
the potential personal liability to which each director of the Company that signed the Registration Statement and the executive officers
of the Company may be subject in the event that the offering and sales of the ADSs as contemplated in this Agreement or the listing and
trading of the ADSs on the Nasdaq Global Select Market were deemed not to be in compliance with the PRC Mergers and Acquisitions Rules.
(yy) Except
as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, the sale of the ADSs and the Ordinary
Shares represented thereby, the listing and trading of the ADSs on the Nasdaq Global Select Market and the consummation of the transactions
contemplated by this Agreement and the Deposit Agreement are not and will not be at the Closing Date or any Option Closing Date adversely
affected by the M&A Rules.
(zz) Each
of the Company and its subsidiaries that were incorporated outside of the PRC has taken, or is in the process of taking, reasonable steps
to comply with, and to ensure compliance by each of its shareholders, option holders, directors, officers and employees that is, or is
directly or indirectly owned or controlled by, a PRC resident or PRC citizen with any applicable rules and regulations of the relevant
PRC government agencies (including but not limited to the Ministry of Commerce, the National Development and Reform Commission and the
State Administration of Foreign Exchange) relating to overseas investment by PRC residents and citizens or the repatriation of the proceeds
from overseas offering and listing by offshore special purpose vehicles controlled directly or indirectly by PRC companies and individuals,
such as the Company (the “PRC Overseas Investment and Listing Regulations”), including without limitation, requesting
each shareholder, option holder, director, officer and employee that is, or is directly or indirectly owned or controlled by, a PRC resident
or citizen to complete any registration and other procedures required under applicable PRC Overseas Investment and Listing Regulations.
(aaa) Except
as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no affiliations or associations
between any member of FINRA and the Company; there are no affiliations or associations between (i) any member of FINRA and (ii) any
of the Company’s officers, directors or, to the knowledge of the Company, 5% or greater security holders or any beneficial owner
of the Company’s unregistered equity securities that were acquired at any time on or after the 180th day immediately preceding the
date the Registration Statement was initially filed with the Commission.
(bbb) Except
for any taxes imposed on any Underwriter by the PRC, Hong Kong, or the Cayman Islands as a result of any present or former connection
(other than any connection resulting from the transactions contemplated by this Agreement) between such Underwriter and the jurisdiction
imposing such taxes, no stamp, documentary, issuance, registration, transfer, withholding, capital gains, income or other taxes or duties
are payable by or on behalf of the Underwriters, the Company or any of its subsidiaries in the Cayman Islands, Hong Kong or the PRC, or
to any taxing authority thereof or therein, in connection with (i) the execution, delivery or consummation of this Agreement, (ii) the
sale and delivery of the ADSs to the Underwriters or purchasers procured by the Underwriters, or (iii) the resale and delivery of
the ADSs by the Underwriters in the manner contemplated herein.
(ccc) Based
on the manner in which the Company currently conducts its business, the expected composition of the Company's income and assets and the
expected value of the Company’s assets (including goodwill, which is based on the expected price of the ADSs in this offering),
the Company does not expect to be a “passive foreign investment company” for U.S. federal income tax purposes for its current
taxable year.
(ddd) It
is not necessary under the laws of the Cayman Islands (i) to enable the Underwriters to enforce their rights under this Agreement
or to enable any holder of ADSs to enforce their respective rights thereunder, provided that they are not otherwise engaged in business
in the Cayman Islands, or (ii) solely by reason of the execution, delivery or consummation of this Agreement, for any of the Underwriters
or any holder of ADSs or Ordinary Shares to be qualified or entitled to carry out business in the Cayman Islands.
(eee) Under
the laws of the Cayman Islands, each holder of ADRs evidencing ADSs issued pursuant to the Deposit Agreement shall be entitled, subject
to the Deposit Agreement, to seek enforcement of its rights through the Depositary or its nominee registered as representative of the
holders of the ADRs in a direct suit, action or proceeding against the Company.
(fff) Each
of this Agreement and the Deposit Agreement is in proper form under the laws of the Cayman Islands for the enforcement thereof against
the Company; and to ensure the legality, validity, enforceability or admissibility into evidence in Cayman Islands of this Agreement and
the Deposit Agreement, it is not necessary that this Agreement or the Deposit Agreement be filed or recorded with any court or other authority
in the Cayman Islands or that any stamp or similar tax in the Cayman Islands be paid on or in respect of this Agreement, the Deposit Agreement
or any other documents to be furnished hereunder, except for nominal stamp duty if the documents are executed in or brought into the Cayman
Islands.
(ggg) The
Company is a “foreign private issuer” as defined in Rule 405 of the Securities Act.
(hhh) Except
as described under the section “Enforceability of Civil Liabilities” in the Time of Sale Prospectus and the Prospectus, the
courts of the Cayman Islands, Hong Kong and the PRC would recognize as a valid judgment any final monetary judgment obtained against the
Company in the courts of the State of New York.
(iii) Neither
the Company nor any of its Subsidiaries nor any of its or their properties or assets has any immunity from the jurisdiction of any court
or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise)
under the laws of the Cayman Islands, Hong Kong or the PRC. The irrevocable and unconditional waiver and agreement of the Company contained
in Section 21(a) not to plead or claim any such immunity in any legal action, suit or proceeding based on this Agreement is
valid and binding under the laws of the Cayman Islands, Hong Kong and the PRC.
(jjj) The
choice of law of the State of New York as the governing law of this Agreement is a valid choice of law under the laws of the Cayman Islands,
Hong Kong and the PRC and will be honored by the courts of the Cayman Islands, Hong Kong and the PRC, subject to the discretion of the
relevant courts and public policies and other principles to be considered by such courts and the other conditions described under the
section titled “Enforceability of Civil Liabilities” in the Time of Sale Prospectus. The Company has the power to submit,
and pursuant to Section 21(a) has, to the extent permitted by law, legally, validly, effectively and irrevocably submitted,
to the jurisdiction of the Specified Courts (as defined in Section 21(a)), and has the power to designate, appoint and empower, and
pursuant to Section 21(b), has legally, validly and effectively designated, appointed and empowered an agent for service of process
in any suit or proceeding based on or arising under this Agreement in any of the Specified Courts.
(kkk) No
forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act)
contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus (including all amendments and supplements thereto)
has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
(lll) The
Company is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act and timely
files reports with the Commission on the Electronic Data Gathering, Analysis, and Retrieval (EDGAR)
system.
2. Representations
and Warranties of the Selling Shareholders. Each Selling Shareholder represents and warrants to and agrees with each of the Underwriters
that:
(a) Such
Selling Shareholder has, and on the Closing Date and each Option Closing Date will have, valid and unencumbered title to the ADSs and
Ordinary Shares represented thereby to be delivered by such Selling Shareholder on such Closing Date or Option Closing Date and full
right, power and authority to enter into this Agreement and, assuming effectiveness of the Registration Statement and the ADS Registration
Statement, to sell, assign, transfer and deliver the ADSs and Ordinary Shares represented thereby to be delivered by such Selling Shareholder
on such Closing Date or Option Closing Date hereunder, and to deposit with the Depositary the Ordinary Shares represented by such ADSs;
and upon the delivery of and payment for the ADSs on the Closing Date or Option Closing Date hereunder, the several Underwriters will
acquire valid and unencumbered title to the ADSs and Ordinary Shares represented thereby to be delivered by such Selling Shareholder
on such Closing Date.
(b) This
Agreement has been duly authorized, executed and delivered by or on behalf of such Selling Shareholder.
(c) The
execution and delivery by such Selling Shareholder of, and the performance by such Selling Shareholder of its obligations under, this
Agreement will not contravene any provision of applicable law, or the memorandum and articles of association or other constitutive documents
of such Selling Shareholder (if such Selling Shareholder is a corporation), or any agreement or other instrument binding upon such Selling
Shareholder or any judgments, orders, decrees or writs, guidelines or notices of any arbitrator, court, governmental body, regulatory
body, administrative agency or other authority, body or agency having jurisdiction over such Selling Shareholder, except for any such
conflict, breach, violation or default that would not, individually or in the aggregate, have a material adverse effect on the Selling
Shareholders’ ability to fulfill its obligations under this Agreement.
(d) No
consent, approval, authorization or order of, or filing with, any person (including any governmental agency or body or any court) is required
to be obtained or made by such Selling Shareholder for the consummation of the transactions contemplated by this Agreement in connection
with the offering and sale of the ADSs sold by such Selling Shareholder, except as may be required by the securities or Blue Sky laws
of the various states of the United States in connection with the offer and sale of the ADSs.
(e) (i) The
Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not contain any
untrue statement of a material fact relating to such Selling Shareholder or omit to state a material fact required to be stated therein
or necessary to make the statements therein relating to such Selling Shareholder not misleading, (ii) the Time of Sale Prospectus
does not, and at the time of each sale of the Offered Securities in connection with the offering when the Prospectus is not yet available
to prospective purchasers, at the Closing Date and at each Option Date, the Time of Sale Prospectus, as then amended or supplemented by
the Company, if applicable, will not, contain any untrue statement of a material fact relating to such Selling Shareholder or omit to
state a material fact necessary to make the statements therein relating to such Selling Shareholder, in the light of the circumstances
under which they were made, not misleading, (iii) each broadly available road show, if any, when considered together with the Time
of Sale Prospectus, does not contain any untrue statement of a material fact relating to such Seller Shareholder or omit to state a material
fact relating to such Seller Shareholder necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading and (iv) the Prospectus does not contain and, as amended or supplemented, if applicable, will not contain
any untrue statement of a material fact relating to such Selling Shareholder or omit to state a material fact necessary to make the statements
therein relating to such Selling Shareholder, in the light of the circumstances under which they were made, not misleading, except that
the representations and warranties set forth in this paragraph shall only apply to any statements or omissions made in reliance upon and
in conformity with information furnished in writing to the Representatives by such Selling Shareholder expressly for use therein, and
it being understood and agreed that the only information furnished by such Selling Shareholder consists of the information with respect
to such Selling Shareholder under the caption headed “Principal and Selling Shareholders” in the Registration Statement, the
Time of Sale Prospectus and the Prospectus (such information, the “Selling Shareholder Information”).
(f) The
sale of the ADSs by such Selling Shareholder pursuant to this Agreement is not prompted by any material information concerning the Company
or any of its Subsidiaries that is not set forth in the in the Registration Statement, the Time of Sale Prospectus and the Prospectus.
(g) Such
Selling Shareholder has no affiliations or associations with any member of FINRA.
(h) There
are no contracts, agreements or understandings between such Selling Shareholder and any person that would give rise to a valid claim against
such Selling Shareholder or any Underwriter for a brokerage commission, finder’s fee or other like payment in connection with this
offering.
(i) Such
Selling Shareholder has not taken, directly or indirectly, any action that is designed to or that has constituted or that would reasonably
be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of the ADSs.
(j) Upon
(i) payment for the ADSs to be sold by such Selling Shareholder pursuant to this Agreement, (ii) issuance of the ADSs pursuant
to the Deposit Agreement, (iii) delivery of ADSs, as directed by the Underwriters, to Cede & Co. (“Cede”)
or such other nominee as may be designated by the Depository Trust Company (“DTC”), (iv) registration of such
ADSs in the name of Cede or such other nominee, and (v) the crediting of such ADSs on the books of DTC to securities accounts of
the Underwriters (assuming that neither the Depositary, DTC nor any such Underwriter has notice of any adverse claim (within the meaning
of Section 8-105 of the New York Uniform Commercial Code (the “UCC”)) to such ADSs), (A) DTC shall be a “protected
purchaser” of such ADSs and the Shares represented thereby within the meaning of Section 8-303 of the UCC, (B) under Section 8-501
of the UCC, the Underwriters will acquire a valid security entitlement in respect of such ADSs and the Shares represented thereby and
(C) no action based on any “adverse claim,” within the meaning of Section 8-102 of the UCC, to such ADSs or the
Shares represented thereby may be asserted against the Underwriters with respect to such security entitlement; for purposes of this representation,
such Selling Shareholder may assume that when such payment, delivery, issuance and crediting occur, (x) such ADSs will have been
registered in the name of Cede or another nominee designated by DTC, in each case on the Depositary’s registry in accordance with
the Depositary Agreement and applicable law, (y) DTC will be registered as a “clearing corporation” within the meaning
of Section 8-102 of the UCC and (z) appropriate entries to the accounts of the several Underwriters on the records of DTC will
have been made pursuant to the UCC.
(k) No
transaction, stamp, capital or other documentary, issuance, registration, transaction, transfer, withholding, capital gains, income or
other taxes or duties are payable by or on behalf of the Underwriters to the jurisdiction of organization or tax residence of the Selling
Shareholder, the government of the PRC, the United States, Hong Kong or the Cayman Islands or any political subdivision or taxing authority
thereof in connection with (i) the sale and delivery of the ADSs by such Selling Shareholder or the deposit of the Ordinary Shares
represented by the ADSs by such Selling Shareholder with the Depositary under the Deposit Agreement, the issuance of the ADSs of such
Selling Shareholder by the Depositary, and the delivery of the ADSs to or for the account of the Underwriters, (ii) the purchase
from the Selling Shareholder of the ADSs and the initial resale and delivery of the ADSs of such Selling Shareholder to purchasers thereof
by the Underwriters or (iii) the execution, delivery or performance of this Agreement, except that Cayman Islands and PRC stamp duty
may be payable in the event that this Agreement is executed in or brought within the jurisdiction of the Cayman Islands or the PRC, as
applicable.
(l) Such
Selling Shareholder has not distributed or will not distribute, prior to the later of the Closing Date, the latest Option Closing Date
and the completion of the Underwriters’ distribution of the ADSs, any offering material in connection with the offering and sale
of the ADSs by such Selling Shareholder, including any free writing prospectus.
(m) Other
than as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, such Selling Shareholder does not have
any registration or other similar rights to have any equity or debt securities registered for sale by the Company.
(n) Such
Selling Shareholder does not have, or has waived prior to the date hereof, any preemptive right, co-sale right or right of first refusal
or other similar right to purchase any of the ADSs that are to be sold by any other Selling Shareholder or the Ordinary Shares represented
thereby to the Underwriters pursuant to this Agreement; and such Selling Shareholder does not own any warrants, options or similar rights
to acquire, and does not have any right or arrangement to acquire, any shares, right, warrants, options or other securities from the Company,
except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus.
(o) As
of the date hereof, no affiliate of such Selling Shareholder (except for the other Selling Shareholder) is the registered or legal owner
of any Ordinary Shares.
(p) None
of such Selling Shareholder or its subsidiaries, or any director or officer thereof, or, to such Selling Shareholder’s knowledge,
any employee, agent or representative thereof or their respective affiliates, is aware of or has taken or will take any action, directly
or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practice Act of 1977, as amended, and the rules of
regulations thereunder, the U.K. Bribery Act 2010, as amended, and the rules and regulations thereunder, or any other applicable
anti-corruption law in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt
of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any Government Official)
in order to influence official action, or to any person in violation of any applicable anti-corruption laws; and (ii) such Selling
Shareholder and its subsidiaries and its and their affiliates have conducted their businesses in compliance with applicable anti-corruption
laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve
compliance with such laws and with the representations and warranties contained herein.
(q) The
operations of such Selling Shareholder and its subsidiaries are and have been conducted at all times in material compliance with all applicable
Anti-Money Laundering Laws, and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or
body or any arbitrator involving such Selling Shareholder or any of its subsidiaries with respect to the Anti-Money Laundering Laws is
pending or, to the best knowledge of such Selling Shareholder, threatened.
(r) (i) Neither
such Selling Shareholder nor any of its subsidiaries, nor any director, officer thereof, nor, to the knowledge of such Selling Shareholder,
any employee, agent, affiliate or representative of such Selling Shareholder or any of its subsidiaries, is or undertakes any business
with a Person that is, or is owned or controlled by one or more Persons that are:
(A) subject
to or the target of any Sanctions, including without limitation individuals or entities named on OFAC’s Specially Designated Nationals
and Blocked Persons List, Foreign Sanctions Evaders List, and Sectoral Sanctions Identifications List, or
(B) located,
organized or resident in a Sanctioned Country.
(ii) Such
Selling Shareholder and its subsidiaries will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other Person:
(A) to
fund or facilitate any dealings, activities or business in, with or relating to any country, territory or Person that, at the time of
such funding or facilitation, is the subject of Sanctions; or
(B) in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).
(iii) For
the past five years, such Selling Shareholder and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and
will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction
is or was the subject of Sanctions.
(iv) No
investigation, inquiry, action or suit or proceeding by or before any Governmental Entity, involving any actual or alleged violations
of any Sanctions by such Selling Shareholder or its subsidiaries, is pending, or to the knowledge of such Selling Shareholder, threatened.
3. Agreements
to Sell and Purchase. Each Selling Shareholder, severally and not jointly, hereby agrees to sell to the several Underwriters, and
each Underwriter, upon the basis of the representations and warranties herein contained,
but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from each Selling Shareholder at US$16.393
per ADS (the “Purchase Price”) the number of Firm ADSs (subject to such adjustments to eliminate fractional shares
as the Representatives may determine) that bears the same proportion to the number of Firm ADSs to be sold by each Selling Shareholder
as the number of Firm ADSs set forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm
ADSs.
On the basis of the representations and warranties
contained in this Agreement, and subject to its terms and conditions, the Selling Shareholders agree to sell to the Underwriters the
Additional ADSs, and the Underwriters shall have the right to purchase, severally and not jointly, up to 1,500,000 Additional
ADSs at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional ADSs shall be reduced
by an amount per share equal to any dividends declared by the Company and payable on the Firm ADSs but not payable on such Additional
ADSs. The Representatives may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written
notice not later than 30 days after the date of this Agreement. Any exercise notice shall specify the number of Additional ADSs to be
purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business
day after the written notice is given and may not be earlier than the closing date for the Firm ADSs nor later than ten business days
after the date of such notice. On each day, if any, that Additional ADSs are to be purchased (an “Option Closing Date”),
each Underwriter agrees, severally and not jointly, to purchase the number of Additional ADSs (subject to such adjustments to eliminate
fractional shares as the Representatives may determine) that bears the same proportion to the total number of Additional ADSs to be purchased
on such Option Closing Date as the number of Firm ADSs set forth in Schedule I hereto opposite the name of such Underwriter bears
to the total number of Firm ADSs.
The Company hereby agrees that, without the prior
written consent of the Representatives on behalf of the Underwriters, it will not, during the period ending 90 days after the date of
the Prospectus (the “Restricted Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, any ADSs or Ordinary Shares beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act)
or any other securities so owned convertible into or exercisable or exchangeable for ADSs or Ordinary Shares or (2) enter into any
swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the ADSs or
Ordinary Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of ADSs,
Ordinary Shares or such other securities, in cash or otherwise or (3) file any registration statement with the Commission relating
to the offering of any ADSs or Ordinary Shares or any securities convertible into or exercisable or exchangeable for ADSs or Ordinary
Shares (other than registration statements on Form S-8 relating to the issuance, vesting, exercise or settlement of equity awards
granted or to be granted pursuant to any share incentive plan that is in effect as of the date hereof and disclosed in the Registration
Statement, the Time of Sale Prospectus and the Prospectus).
The restrictions contained in the preceding paragraph
shall not apply to (a) the issuance of Ordinary Shares pursuant to the conversion or exchange of convertible or exchangeable securities
or the exercise of warrants or options (including net exercise), in each case outstanding on the date hereof and described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, provided that the Company shall cause the recipient of such securities
to not sell, transfer, pledge or otherwise dispose his or her interest in such securities during the Restricted Period; (ii) the
issuance of Ordinary Shares or securities convertible into or exercisable for Ordinary Shares (whether upon the exercise of stock options
or otherwise) or the grant of options to purchase Ordinary Shares or other equity-based compensation pursuant to a share incentive plan
that is in effect as of the date hereof and disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, provided
that the Company shall cause the recipient of such securities to not sell, transfer, pledge or otherwise dispose his or her interest in
such securities during the Restricted Period; (iii) the deposit of Ordinary Shares with the Depositary for conversion into ADSs in
connection with the contemplated issuance of options under the Company’s equity incentive plan that is in effect as of the date
hereof and disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus; and (iv) facilitating the establishment
of a trading plan on behalf of a shareholder, officer or director of the Company pursuant to Rule 10b5-1 under the Exchange Act for
the transfer of Ordinary Shares or ADSs of the Company, provided that (a) such plan does not provide for the transfer of ordinary
shares or ADSs during the Restricted Period and (b) no public announcement or filing under the Exchange Act is required of or voluntarily
made by or on behalf of the Company regarding the establishment of such plan.
4. Terms
of Public Offering. The Company and Selling Shareholders are advised by the Representatives
that the Underwriters propose to make a public offering of their respective portions of the ADSs as soon after this Agreement has become
effective as in the judgment of the Representatives is advisable. The Company and Selling Shareholders are further advised by the Representatives
that the ADSs are to be offered to the public initially at US$16.90 per ADS (the “Public Offering Price”).
Certain of the Underwriters are expected to make offers and sales both inside and outside the United States through their respective
selling agents. Any offers or sales in the United States will be conducted by broker-dealers registered with the Commission. CMB International
Capital Limited is not a broker-dealer registered with the Commission. Therefore, CMB International Capital Limited will not make any
offers or sales of ADSs within the United States. In addition, CMB International Capital Limited will not underwrite any of the ADSs
to be sold within the United States.
5. Payment
and Delivery. Payment for the Firm ADSs to be sold by each Selling Shareholder shall be made to such Selling Shareholder in Federal
or other funds immediately available in New York City to the account specified by such Selling Shareholder to the Underwriters at least
forty-eight hours in advance of such payment against delivery of such Firm ADSs for the respective accounts of the several Underwriters
at 10:00 a.m., New York City time, on June 13, 2024, or at such other time on the same or such other date, not later than June 21,
2024, as shall be designated in writing by the Representatives. The time and date of such payment are hereinafter referred to as the
“Closing Date.”
Payment
for any Additional ADSs shall be made to each Selling Shareholder in Federal or other funds immediately available in New York City to
the account specified by each Selling Shareholder to the Underwriters at least forty-eight hours in advance of such payment against delivery
of such Additional ADSs for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified
in the corresponding notice described in Section 3 or at such other time on the same or on such other date, in any event not later
than July 25, 2024, as shall be designated in writing by the Representatives.
The
Firm ADSs and Additional ADSs shall be registered in such names and in such denominations as the Representatives shall request
in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The
Firm ADSs and Additional ADSs shall be delivered to the Representatives on the Closing Date or an Option Closing Date, as the case may
be, for the respective accounts of the several Underwriters through the facilities of the Depository Trust Company. The Purchase Price
payable by the Underwriters shall be reduced by (i) any transfer taxes paid by, or on behalf of, the Underwriters in connection with
the transfer of the ADSs to the Underwriters duly paid and (ii) any withholding required by law.
6. Conditions
to the Underwriters’ Obligations. The several obligations of the Underwriters are subject
to the following conditions:
(a) Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date there shall not have occurred any change, or any development
involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and
its Subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus that, in the judgment of the Representatives, is
material and adverse and that makes it, in the judgment of the Representatives, impracticable to market the ADSs on the terms and in the
manner contemplated in the Time of Sale Prospectus.
(b) The
Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the Company,
to the effect set forth in Section 6(a), Section 6(p) and Section 6(t) and to the effect that the representations
and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied
with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing
Date. The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.
(c) The
Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an authorized signatory of each
Selling Shareholder to the effect that the representations and warranties of the Selling Shareholder contained in this Agreement are true
and correct as of the Closing Date and that such Selling Shareholder has complied with all of the agreements and satisfied all of the
conditions on its part to be performed or satisfied hereunder on or before the Closing Date.
(d) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Davis Polk & Wardwell, U.S.
counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.
(e) The
Underwriters shall have received on the Closing Date an opinion of Maples and Calder (Hong Kong) LLP, Cayman Islands counsel for the Company,
dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.
(f) The
Underwriters shall have received on the Closing Date an opinion of JunHe LLP, PRC counsel for the Company, dated the Closing Date, in
form and substance reasonably satisfactory to the Underwriters.
(g) The
Underwriters shall have received on the Closing Date an opinion of Davis Polk & Wardwell, Hong Kong counsel for the Company,
dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.
(h) The
Underwriters shall have received on the Closing Date an opinion of Kirkland & Ellis LLP, U.S. counsel for the Selling Shareholders,
dated the Closing Date, in form and substance satisfactory to the Underwriters.
(i) The
Underwriters shall have received on the Closing Date an opinion of JunHe LLP, PRC counsel for the Selling Shareholders, dated the Closing
Date, in form and substance satisfactory to the Underwriters.
The opinions of counsel for the Company (except
for the opinion of PRC counsel for the Company) described above shall be rendered to the Underwriters at the request of the Company, and
shall so state therein.
(j) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Latham & Watkins LLP, U.S. counsel
for the Underwriters, dated the Closing Date, in form and substance satisfactory to the Underwriters.
(k) The
Underwriters shall have received on the Closing Date an opinion of Zhong Lun Law Firm, PRC counsel for the Underwriters, dated the Closing
Date, in form and substance satisfactory to the Underwriters.
(l) The
Underwriters shall have received on the Closing Date an opinion of Emmet, Marvin & Martin LLP, counsel for the Depositary, dated
the Closing Date, in form and substance satisfactory to the Underwriters.
(m) The
Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date,
as the case may be, in form and substance satisfactory to the Underwriters, from KPMG Huazhen LLP, independent public accountants, containing
statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect
to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and
the Prospectus; provided that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than
the date hereof.
(n) The
“lock-up” agreements, each substantially in the form of Exhibit A hereto, between the Company, the Representatives and
the Selling Shareholders relating to sales and certain other dispositions of ADSs, Ordinary Shares or certain other securities, delivered
to the Representatives on or before the date hereof, shall be in full force and effect on the Closing Date.
(o) The
several obligations of the Underwriters to purchase Additional ADSs hereunder are subject to the delivery to the Representatives on the
applicable Option Closing Date of the following:
(i) a
certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered
on the Closing Date pursuant to Section 6(b) hereof remains true and correct as of such Option Closing Date;
(ii) a
certificate, dated the Option Closing Date and signed by an authorized signatory of each Selling Shareholder, confirming that the certificate
delivered on the Closing Date pursuant to Section 6(c) hereof remains true and correct as of such Option Closing Date;
(iii) an
opinion and negative assurance letter Davis Polk & Wardwell, U.S. counsel for the Company, dated the Option Closing Date, relating
to the Additional ADSs to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 6(d) hereof;
(iv) an
opinion of Maples and Calder (Hong Kong) LLP, Cayman Islands counsel for the Company, dated the Option Closing Date, relating to the Additional
ADSs to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 6(e) hereof;
(v) an
opinion of JunHe LLP, PRC counsel for the Company, dated the Option Closing Date, relating to the Additional ADSs to be purchased on such
Option Closing Date and otherwise to the same effect as the opinion required by Section 6(f) hereof;
(vi) an
opinion of Davis Polk & Wardwell, Hong Kong counsel for the Company, dated the Option Closing Date, relating to the Additional
ADSs to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 6(g) hereof;
(vii) an
opinion and negative assurance letter of Latham & Watkins LLP, U.S. counsel for the Underwriters, dated the Option Closing Date,
relating to the Additional ADSs to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by
Section 6(j) hereof;
(viii) an
opinion of Zhong Lun Law Firm, PRC counsel for the Underwriters, dated the Option Closing Date, relating to the Additional ADSs to be
purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 6(k) hereof;
(ix) an
opinion of Emmet, Marvin & Martin LLP, counsel for the Depositary, dated the Option Closing Date, relating to the Additional
ADSs to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 6(l) hereof;
(x) a
letter dated the Option Closing Date, in form and substance satisfactory to the Underwriters, from KPMG Huazhen LLP, independent public
accountants, substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section 6(m) hereof;
provided that the letter delivered on the Option Closing Date shall use a “cut-off date” not earlier than three business
days prior to such Option Closing Date;
(xi) an
opinion of Kirkland & Ellis LLP, U.S. counsel for the Selling Shareholders, dated the Option Closing Date, relating to the Additional
ADSs to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 6(h) hereof;
(xii) an
opinion of JunHe LLP, PRC counsel for the Selling Shareholders, dated the Option Closing Date, relating to the Additional ADSs to be purchased
on such Option Closing Date and otherwise to the same effect as the opinion required by Section 6(i) hereof; and
(xiii) such
other documents as the Representatives may reasonably request with respect to the good standing of the Company, the due authorization
and issuance of the Additional ADSs to be sold on such Option Closing Date and other matters related to the issuance of such Additional
ADSs.
(p) There
shall not have been any adverse legislative or regulatory developments in the PRC following the signing of this Agreement, which in the
Representatives’ sole judgment in good faith after consultation with the Company, would make it inadvisable or impractical to proceed
with the public offering or the delivery of the ADSs at the Closing Date or any Option Closing Date, as the case may be, on the terms
and in the manner contemplated in this Agreement.
(q) The
Depositary shall have furnished or caused to be furnished to the Underwriters a certificate satisfactory to the Representatives of one
of its authorized officers with respect to the deposit with it of the ADSs against issuance of the ADSs, the execution, issuance, countersignature
and delivery of the ADSs pursuant to the Deposit Agreement and such other matters related thereto as the Representatives may reasonably
request.
(r) The
Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A and Rule 430B under
the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act.
(s) No
free writing prospectus, Prospectus or amendment or supplement to the Registration Statement, the ADS Registration Statement or the Prospectus
shall have been filed to which the Representatives object in writing.
(t) No
stop order suspending the effectiveness of the Registration Statement, the ADS Registration Statement or any post-effective amendment
to the Registration Statement, shall be in effect and no proceedings for such purpose shall have been instituted or threatened by the
Commission.
(u) FINRA
shall not have raised any objection with respect to the fairness or reasonableness of the underwriting, or other arrangements of the transactions
contemplated hereby.
(v) At
or prior to the Closing Date and each Option Closing Date, the ADSs shall be eligible for clearance and settlement through the facilities
of the DTC.
(w) On
the Closing Date or Option Closing Date, as the case may be, the Representatives and counsel for the Underwriters shall have received
such information, documents, certificates and opinions as they may reasonably require for the purposes of enabling them to pass upon the
accuracy and completeness of any statement in the Registration Statement, the Time of Sale Prospectus and the Prospectus, issuance and
sale of the ADSs as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction
of any of the conditions or agreements, herein contained.
7. Covenants
of the Company. The Company covenants with each Underwriter as follows:
(a) To
comply with the requirements of Rule 430A and Rule 430B, and notify the Representatives immediately, and confirm the notice
in writing, (i) when any post-effective amendment to the Registration Statement, the Form 8-A Registration Statement or the
ADS Registration Statement shall become effective, or any supplement to the Prospectus (including any prospectus wrapper) or any amended
Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission
for any amendment to the Registration Statement, the Form 8-A Registration Statement, the ADS Registration Statement or any amendment
or supplement to the Prospectus or for additional information, (iv) of the issuance by the Commission of any stop order suspending
the effectiveness of the Registration Statement, the Form 8-A Registration Statement, the ADS Registration Statement or any post-effective
amendment or of any order preventing or suspending the use of the preliminary prospectus or the Prospectus, or of the suspension of the
qualification of the ADSs for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of
such purposes or of any examination pursuant to Section 8(e) of the 1933 Act concerning the Registration Statement or the ADS
Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection
with the offering of the ADSs. The Company will effect all filings required under Rule 424(b), in the manner and within the time
period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to
ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission
and, in the event that it was not, it will promptly file such prospectus. The Company will use reasonable efforts to prevent the issuance
of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.
(b) To
furnish to the Representatives, without charge, copies of the Registration Statement (including exhibits thereto and documents incorporated
by reference therein that are filed together with the Registration Statement) and for delivery to each other Underwriter a copy of the
Registration Statement (without exhibits thereto) and to furnish to the Representatives in New York City, without charge, prior to 10:00 a.m. New
York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section 7(i) or
7(j) below, as many copies of the Time of Sale Prospectus, the Prospectus and documents incorporated by reference therein and any
supplements and amendments thereto or to the Registration Statement as the Representatives may reasonably request.
(c) Before
amending or supplementing the Registration Statement, the ADS Registration Statement, the Form 8-A Registration Statement, the Time
of Sale Prospectus or the Prospectus, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to
file any such proposed amendment or supplement to which the Representatives reasonably object.
(d) To
give the Representatives notice of its intention to make any filing pursuant to the Exchange Act prior to or on the later of the Closing
Date or any Option Closing Date and to furnish the Representatives with copies of any such documents a reasonable amount of time prior
to such proposed filing, and not to file or use any such document to which the Representatives or counsel for the Underwriters shall reasonably
object.
(e) To
furnish to the Representatives a copy of each proposed free writing prospectus (including any electronic roadshow), or amendment thereof
or supplement thereto, to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed
free writing prospectus to which the Representatives reasonably object.
(f) If
at any time following issuance of a free writing prospectus there occurred or occurs an event or development as a result of which such
free writing prospectus conflicted or would conflict with the information contained in the Registration Statement or the ADS Registration
Statement relating to the ADSs or included or would include an untrue statement of a material fact or omitted or would omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances, prevailing at that subsequent time,
not misleading, to promptly notify the Representatives and to promptly (subject to Section 7(c)) amend or supplement, at its own
expense, such free writing prospectus to eliminate or correct such conflict, untrue statement or omission.
(g) Not
to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under
the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have
been required to file thereunder.
(h) Not
to (and to cause its affiliates not to) take, directly or indirectly, any action which is designed to or which constitutes or which would
reasonably be expected to cause or result in stabilization or manipulation of the price of any security of the Company or facilitate the
sale or resale of the ADSs.
(i) If
the Time of Sale Prospectus is being used to solicit offers to buy the ADSs at a time when the Prospectus is not yet available to prospective
purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus
in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall occur or condition exist
as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file,
or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with
applicable law, forthwith to prepare, file with the Commission (subject to the last clause of this subsection (i)) and furnish, at its
own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that
the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time
of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented,
will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply
with applicable law; to promptly give the Representatives written notice of any such event or condition of which the Company becomes aware;
and before amending or supplementing the Time of Sale Prospectus, to furnish to the Representatives a copy of each such proposed amendment
or supplement and not to file any such proposed amendment or supplement to which the Representatives reasonably object.
(j) If,
during such period after the first date of the public offering of the ADSs as in the opinion of counsel for the Underwriters the Prospectus
(or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection
with sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement
the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the
notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion
of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare,
file with the Commission (subject to the last clause of this subsection (j)) and furnish, at its own expense, to the Underwriters and
to the dealers (whose names and addresses the Representatives will furnish to the Company) to which ADSs may have been sold by the Representatives
on behalf of the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements
in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the
notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus,
as amended or supplemented, will comply with applicable law; to promptly give the Representatives written notice of any such event or
condition of which the Company becomes aware; and before amending or supplementing the Prospectus, to furnish to the Representatives a
copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the Representatives
reasonably object.
(k) To
endeavor to qualify the ADSs for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall
reasonably request.
(l) To
make generally available to the Company’s security holders and to the Representatives as soon as practicable an earnings statement
covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement
which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission
thereunder. The Company, during the period when the Prospectus is required to be delivered under the Securities Act, will file all documents
required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and the applicable
rules and regulations of the Commission thereunder. During the three-year period after the date of this Agreement, the Company will
furnish to the Representatives and, upon request, to each of the other Underwriters, as soon as practicable after the end of each fiscal
year, a copy of its annual report to shareholders for such year; and the Company will furnish to the Representatives (i) as soon
as available, a copy of each report of the Company filed with the Commission under the Exchange Act or mailed to shareholders, and (ii) from
time to time, such other information concerning the Company as the Representatives may reasonably request. However, so long as the Company
is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act and is timely filing
reports with the Commission on its EDGAR reporting system, it is not required to furnish such reports or statements filed through EDGAR
to the Underwriters.
(m) Not
to facilitate any shareholder’s conversion of Ordinary Shares to ADSs during the Restricted Period and not to release the Depositary
from the obligations set forth in, or otherwise amend, terminate or fail to enforce, the Depositary Agreement without the prior written
consent of the Representatives. The Company shall at all times maintain transfer restrictions with respect to the ADSs and Ordinary Shares
that are subject to transfer restrictions pursuant to this Agreement and the “lock-up” agreements referred to in Section 6(n) and
shall ensure compliance with such restrictions on transfer of restricted ADSs and Ordinary Shares. The Company shall retain all share
certificates that are by their terms subject to transfer restrictions until such time as such transfer restrictions are no longer applicable
to such securities.
(n) To
promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (a) completion
of the distribution of the ADSs within the meaning of the Securities Act and (b) completion of the Restricted Period.
(o) If
at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development
as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or
omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing
at that subsequent time, not misleading, to promptly notify the Representatives and will promptly amend or supplement, at its own expense,
such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.
(p) To
comply with the terms of the Deposit Agreement so that the ADSs will be issued by the Depositary and delivered to each Underwriter’s
participant account in DTC, pursuant to this Agreement on the Closing Date and each applicable Option Closing Date.
(q) (i) To
not attempt to avoid any judgment in connection with this Agreement obtained by it, applied to it, or denied to it in a court of competent
jurisdiction outside the Cayman Islands; (ii) following the consummation of the offering, to use its reasonable efforts to obtain
and maintain all approvals required in the Cayman Islands to pay and remit outside the Cayman Islands all dividends declared by the Company
and payable on the Ordinary Shares, if any; and (iii) to use its reasonable efforts to obtain and maintain all approvals, if any,
required in the Cayman Islands for the Company to acquire sufficient foreign exchange for the payment of dividends and all other relevant
purposes.
(r) To
comply with the PRC Overseas Investment and Listing Regulations, and to use its reasonable efforts to cause holders of its Ordinary Shares
that are, or that are directly or indirectly owned or controlled by, Chinese residents or Chinese citizens, to comply with the PRC Overseas
Investment and Listing Regulations applicable to them, including, without limitation, requesting each such shareholder to complete any
registration and other procedures required under applicable PRC Overseas Investment and Listing Regulations (including any applicable
rules and regulations of the SAFE).
(s) Upon
request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company’s trademarks,
service marks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the offering
of the ADSs.
(t) To
use its reasonable efforts to comply with and will use its reasonable efforts to require the Company’s directors and executive officers,
in their capacities as such, to comply with all applicable laws, rules and regulations, including, without limitation, the Sarbanes-Oxley
Act.
(u) That
all sums payable by the Company under this Agreement shall be paid free and clear of and without deductions or withholdings of any present
or future taxes or duties, unless the deduction or withholding is required by law, in which case the Company shall pay such additional
amount as will result in the receipt by each Underwriter of the full amount that would have been received had no deduction or withholding
been made, except to the extent of taxes that are imposed by reason of a present or former connection between the recipient and the jurisdiction
imposing such taxes (other than a connection that would not have arisen but for the transactions contemplated by this Agreement).
(v) That
all sums payable to an Underwriter shall be considered exclusive of any value added or similar taxes. Where the Company is obliged to
pay value added or similar tax on any amount payable hereunder to an Underwriter, upon receipt of value added or similar tax receipts,
the Company shall in addition to the sum payable hereunder pay an amount equal to any applicable value added or similar tax.
(w) If
the third anniversary of the initial effective date of the Registration Statement occurs before all the ADSs have been sold by the Underwriters,
prior to the third anniversary to file a new shelf registration statement and to take any other action necessary to permit the public
offering of the Shares to continue without interruption; references herein to the Registration Statement shall include the new registration
statement declared effective by the Commission.
8. Covenants
of the Selling Shareholders. Each Seller, severally and not jointly, covenants with each Underwriter as follows:
(a) To
deliver to each Underwriter (or its agent), prior to or at the Closing Date, a properly completed and executed Internal Revenue Service
(“IRS”) Form W-9 or an applicable IRS Form W-8, as appropriate, together with all required attachments to such form,
establishing a complete exemption from United States backup withholding tax.
(b) To
indemnify and hold the Underwriters harmless against, any stamp, issue, registration, documentary, transfer or other similar taxes or
duties imposed under the laws of Cayman Islands, Hong Kong or the PRC or any political sub-division or taxing authority thereof or therein
that is payable in connection with (i) the execution, delivery, consummation or enforcement of this Agreement or the Deposit Agreement
or (ii) the sale and delivery of the ADSs to the Underwriters or purchasers procured by the Underwriters.
9. Expenses.
Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, the Selling Shareholders,
jointly and severally, agree to pay or cause to be paid all expenses incident to the performance of their and the Company’s obligations
under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s counsel, the Company’s accountants
in connection with the registration and delivery of the ADSs and Ordinary Shares represented thereby under the Securities Act and all
other fees or expenses in connection with the preparation and filing of the Time of Sale Prospectus, the Prospectus, any free writing
prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing,
including all printing costs associated therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers,
in the quantities hereinabove specified, (ii) the fees, disbursements and expenses of the Selling Shareholders’ counsel in
connection with the offering of the ADSs and the execution, delivery and performance of this Agreement, (iii) the fees, disbursements
and expenses of the Underwriters’ counsel in connection with the offering of the ADSs and the execution, delivery and performance
of this Agreement to the following extent: if the aggregate public offering price of the ADSs is greater than US$100 million, then none
of such fees, disbursements and expenses; if the aggregate public offering price of the ADSs is less than or equal to US$100 million,
then 50% of such fees, disbursements and expenses; and if the transactions contemplated by this Agreement are not consummated, then two-thirds
of such fees, disbursements and expenses, (iv) fees and expenses associated with a book-building system and deal roadshow link,
which shall not exceed US$20,000, (v) all costs and expenses related to the transfer and delivery of the ADSs to the Underwriters,
including any transfer or other similar taxes payable thereon, (vi) the cost of printing or producing any Blue Sky or Legal Investment
memorandum in connection with the offer and sale of the ADSs under state securities laws and all expenses in connection with the qualification
of the ADSs for offer and sale under state securities laws as provided in Section 7(k) hereof, including filing fees and the
reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue
Sky or Legal Investment memorandum, (vii) all filing fees and fees and disbursements of counsel to the Underwriters incurred in
connection with the review and qualification of the offering of the ADSs by the Financial Industry Regulatory Authority, (viii) the
cost of printing certificates representing the ADSs or Ordinary Shares represented thereby, (ix) the costs and charges of any transfer
agent, registrar or depositary and (x) the document production charges and expenses associated with printing this Agreement. Any
fees and expenses to be paid or reimbursed by the Selling Shareholders shall be based on reasonable supporting documentation to be provided
by the relevant parties to the Selling Shareholders, and approved by the Selling Shareholders. It is understood, however, that except
as provided in this Section 9, Section 11 entitled “Indemnity and Contribution” and the last paragraph of Section 14
below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel, share transfer taxes
payable on resale of any of the ADSs by them and any advertising expenses connected with any offers they may make.
10. Covenants
of the Underwriters. Each Underwriter severally covenants with the Company not to take any action that would result in the Company
being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter
that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.
11. Indemnity
and Contribution. (a) The Company agrees to indemnify and
hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section 15 of the
Securities Act or Section 20 of the Exchange Act, and each affiliate of any Underwriter within the meaning of Rule 405 under
the Securities Act, and each of their respective directors, officers and employees, from and against any and all losses, claims, damages
and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating
any such action or claim), joint or several, caused by any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement or any amendment thereof, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer
free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed,
or is required to file, pursuant to Rule 433(d) under the Securities Act, any “road show” as defined in Rule 433(h) under
the Securities Act (a “road show”), or the Prospectus or any amendment or supplement thereto, or any Written Testing-the-Waters
Communication or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue
statement or omission or alleged untrue statement or omission based upon information relating to any Underwriter furnished to the Company
in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such
information is that described in Section 11(c);
(b) Each
of the Selling Shareholders agrees, severally and not jointly, to indemnify and hold harmless each Underwriter, each person, if any, who
controls any Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and
each affiliate of any Underwriter within the meaning of Rule 405 under the Securities Act, and each of their respective directors,
officers and employees, from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal
or other expenses reasonably incurred in connection with defending or investigating any such action or claim), joint or several, caused
by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof,
the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule 433(h) under
the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act, any “road show” as defined in Rule 433(h) under the Securities Act (a “road show”),
or the Prospectus or any amendment or supplement thereto, or any Written Testing-the-Waters Communication or caused by any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading,
except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement
or omission based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use therein, it being understood and agreed that the only such information is that described in Section 11(c); provided
that notwithstanding the generality of the foregoing, each Selling Shareholder will only be liable pursuant to this Section 11(b) to
the extent that such losses, claims, damages or liabilities arise out of, or are based upon, any such untrue statement or omission or
alleged untrue statement or omission made in reliance upon and in conformity with the Selling Shareholder Information; provided, further,
that the liability of each Selling Shareholder for indemnity under this subsection shall not exceed the net proceeds received by such
Selling Shareholder (after underwriting commissions and discounts) from its sale of the ADSs hereunder.
(c) Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, the directors of the Company, the officers
of the Company who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section 15
of the Securities Act or Section 20 of the Exchange Act, and each Selling Shareholder and each person, if any, who controls any Selling
Shareholder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act from and against any and
all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection
with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement or any amendment thereof, the Time of Sale Prospectus or any amendment or supplement thereto,
or any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, or caused by any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, but
only with reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use in the Registration Statement, the Time of Sale Prospectus, any issuer free writing prospectus, road show, or the Prospectus
or any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter through
the Representatives consists of the names and addresses of each Underwriter appearing under the caption “Underwriting” in
the Prospectus.
(d) In
case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity
may be sought pursuant to Section 11(a), 11(b) or 11(c), such person (the “indemnified party”) shall promptly
notify the person against whom such indemnity may be sought (the “indemnifying party”) in writing and the indemnifying
party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified
party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel
related to such proceeding; provided that the failure to notify the indemnifying party shall not relieve it from any liability
that it may have under the preceding paragraphs of this Section 11 except to the extent that it has been materially prejudiced (through
the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to notify the indemnifying
party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the preceding paragraphs of
this Section 11. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses
of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall
have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded parties)
include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interests between them. It is understood that the indemnifying party shall not, in respect of the
legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for
(i) the fees and expenses of more than one separate firm (in addition to any local counsel) for all Underwriters and all persons,
if any, who control any Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange
Act or who are affiliates of any Underwriter within the meaning of Rule 405 under the Securities Act, (ii) the fees and expenses
of more than one separate firm (in addition to any local counsel) for the Company, its directors, its officers who sign the Registration
Statement and each person, if any, who controls the Company within the meaning of either such Section, and (iii) the fees and expenses
of more than one separate firm (in addition to any local counsel) for the Selling Shareholders and each person, if any, who controls any
Selling Shareholder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act and that all such
fees and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for the Underwriters and such control
persons and affiliates of any Underwriters, such firm shall be designated in writing by the Representatives. In the case of any such separate
firm for the Company, and such directors, officers and control persons of the Company, such firm shall be designated in writing by the
Company. In the case of any such separate firm for the Selling Shareholders, and such control persons of the Selling Shareholders, such
firm shall be designated in writing by the Selling Shareholders. The indemnifying party shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the
indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying
party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement
is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party
shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying
party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding
in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified
party, unless such settlement (x) includes an unconditional release of such indemnified party from all liability on claims that are
the subject matter of such proceeding and (y) does not include a statement as to or an admission of fault, culpability or a failure
to act, by or on behalf of any indemnified party.
(e) To
the extent the indemnification provided for in Section 11(a), 11(b) or 11(c) is unavailable to an indemnified party or
insufficient in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying
party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable
by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) (i) in such
proportion as is appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified
party or parties on the other hand from the offering of the ADSs or (ii) if the allocation provided by clause 11(e)(i) above
is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 11(e)(i) above
but also the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other
hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities (or actions in respect
thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company and the Selling Shareholders
on the one hand and the Underwriters on the other hand in connection with the offering of the ADSs shall be deemed to be in the same respective
proportions as the net proceeds from the offering of the ADSs (before deducting expenses) received by the Selling Shareholders on the
one hand and the total underwriting discounts and commissions received by the Underwriters on the other hand, in each case as set forth
in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the ADSs. The relative fault of the Company
and the Selling Shareholders on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates
to information supplied by the Company or the Selling Shareholders or by the Underwriters and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. The Underwriters’ respective obligations
to contribute pursuant to this Section 11 are several in proportion to the respective number of ADSs they have purchased hereunder,
and not joint.
(f) The
Company, the Selling Shareholders and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 11
were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method
of allocation that does not take account of the equitable considerations referred to in Section 11(e). The amount paid or payable
by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to in Section 11(e) shall
be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 11,
no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the ADSs underwritten
by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. The remedies provided for in this Section 11 are not exclusive and shall not limit any rights
or remedies which may otherwise be available to any indemnified party at law or in equity.
(g) The
indemnity and contribution provisions contained in this Section 11 and the representations, warranties and other statements of the
Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this
Agreement, (ii) any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate
of any Underwriter or the Company, its officers or directors or any person controlling the Company and (iii) acceptance of and payment
for any of the ADSs.
12. Termination.
The Underwriters may terminate this Agreement by notice given by the Representatives to the Company and the Selling Shareholders,
if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended
or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE MKT, the Nasdaq Global Select Market
and the London Stock Exchange, (ii) trading of any securities of the Company shall have been suspended on any exchange or in any
over-the-counter market, (iii) a material disruption in securities settlement, payment or clearance services in the United States,
the PRC, Hong Kong, the Cayman Islands or other relevant jurisdiction shall have occurred, (iv) any moratorium on commercial banking
activities shall have been declared by Federal, New York State, Hong Kong, London, PRC, Cayman Islands or other relevant authorities
or (v) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets, currency exchange
rates or controls or any calamity or crisis that, in the judgment of the Representatives, is material and adverse and which, singly or
together with any other event specified in this clause (v), makes it, in the judgment of the Representatives, impracticable or inadvisable
to proceed with the offer, sale or delivery of the ADSs on the terms and in the manner contemplated in the Time of Sale Prospectus or
the Prospectus.
13. Representations,
Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any
investigation made by or on behalf of any Underwriter or its affiliates or selling agents, any person controlling any Underwriter, its
officers or directors, any person controlling the Company and (ii) delivery of and payment for the ADSs.
14. Effectiveness;
Defaulting Underwriters. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.
If,
on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase
ADSs that it has or they have agreed to purchase hereunder on such date, and the aggregate number of ADSs which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the ADSs to be purchased
on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm ADSs set forth opposite their
respective names in Schedule I bears to the aggregate number of Firm ADSs set forth opposite the names of all such non-defaulting
Underwriters, or in such other proportions as the Representatives may specify, to purchase the ADSs which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase on such date; provided that in no event shall the number of ADSs that
any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 14 by an amount in excess
of one-ninth of such number of ADSs without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Firm ADSs and the aggregate number of Firm ADSs with respect to which such default occurs is more than
one-tenth of the aggregate number of Firm ADSs to be purchased on such date, and arrangements satisfactory to the Representatives, the
Company and the Selling Shareholders for the purchase of such Firm ADSs are not made within 36 hours after such default, this Agreement
shall terminate without liability on the part of any non-defaulting Underwriter, the Company or the Selling Shareholders. In any such
case either the Representatives, the Company or the Selling Shareholders shall have the right to postpone the Closing Date, but in no
event for longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus,
in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Additional ADSs and the aggregate number of Additional ADSs with respect to which such default occurs
is more than one-tenth of the aggregate number of Additional ADSs to be purchased on such Option Closing Date, the non-defaulting Underwriters
shall have the option to (i) terminate their obligation hereunder to purchase the Additional ADSs to be sold on such Option Closing
Date or (ii) purchase not less than the number of Additional ADSs that such non-defaulting Underwriters would have been obligated
to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability
in respect of any default of such Underwriter under this Agreement.
15. Entire
Agreement. (a) This Agreement, together with any contemporaneous
written agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the
ADSs, represents the entire agreement among the Company, the Selling Shareholders and the Underwriters with respect to the preparation
of the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the ADSs.
(b) the
Company and Selling Shareholders acknowledge that in connection with the offering of the ADSs: (i) the Underwriters have acted at
arms’ length, are not agents of, and owe no fiduciary duties to, the Company, the Selling Shareholders or any other person, (ii) the
Underwriters owe the Company and Selling Shareholders only those duties and obligations set forth in this Agreement and prior written
agreements (to the extent not superseded by this Agreement), if any, and (iii) the Underwriters may have interests that differ from
those of the Company and the Selling Shareholders. The Company and Selling Shareholders waive to the full extent permitted by applicable
law any claims they may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering
of the ADSs.
16. Trial
by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates),
each of the Selling Shareholders and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.
17. Counterparts.
This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. Delivery of an executed counterpart of a signature or signature page to this Agreement
by facsimile, DocuSign, or other e-signature or electronic transmission (e.g., a “pdf” or “tif”) shall be effective
as delivery of a manually executed counterpart thereof.
18. Applicable
Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.
19. Headings.
The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part
of this Agreement.
20. Notices.
All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed
or sent to the Representatives, at:
BofA Securities, Inc.
One Bryant Park
New York, NY 10036
United States of America
Attention: ECM/ECM Syndicate
Facsimile: +1 (646) 855-3701
CMB International Capital Limited
45/F, Champion Tower
3 Garden Road
Central
Hong Kong
Citigroup Global Markets Inc.
388 Greenwich Street
New York, NY 10013
United States of America
Attention: General Counsel
if to the
Company shall be delivered, mailed or sent to Atour Lifestyle Holdings Limited, 1st floor, Wuzhong Building, 618 Wuzhong Road, Minhang
District, Shanghai, People’s Republic of China, Attention: Legal Department
if to the Selling Shareholders, shall be delivered, mailed or sent
to 16th Floor, Block B, Rongke Information Center, No. 2 South Road of Zhongguancun Academy of Science, Haidian District, Beijing,
PRC, Attention: Lili Tan.
21. Submission
to Jurisdiction; Appointment of Agents for Service. (a) The Company and each Selling Shareholder hereby submit to the exclusive
jurisdiction of any New York State or United States Federal court sitting in Borough of Manhattan in The City of New York (the “Specified
Courts”) over any suit, action or proceeding arising out of or relating to this Agreement, the Prospectus, the Registration
Statement or the offering of the ADSs (each, a “Related Proceeding”). The Company and each of the Selling Shareholders
irrevocably waive, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of
any Related Proceeding brought in such a court and any claim that any such Related Proceeding brought in such a court has been brought
in an inconvenient forum. To the extent that the Company or any Selling Shareholders has or hereafter may acquire any immunity (on the
grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to itself or its property,
the Company or such Selling Shareholders irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any
such suit, action or proceeding.
(b) The
Company and each Selling Shareholder hereby irrevocably appoint Cogency Global Inc. as their respective agent for service of process in
any Related Proceeding and agrees that service of process in any such Related Proceeding may be made upon it at the office of such agent.
The Company and each Selling Shareholder represent and warrant that such agent has agreed to act as their respective agent for service
of process, and the Company and each Selling Shareholder agree to take any and all action, including the filing of any and all documents
and instruments, that may be necessary to continue such appointment in full force and effect.
22. Judgment
Currency. If for the purposes of obtaining judgment in any court it is necessary to convert a sum due hereunder into any currency
other than United States dollars, the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall
be the rate at which in accordance with normal banking procedures the Underwriters could purchase United States dollars with such other
currency in The City of New York on the business day preceding that on which final judgment is given. The obligation of the Company and
each Selling Shareholder with respect to any sum due from it to any Underwriter or any person controlling any Underwriter shall, notwithstanding
any judgment in a currency other than United States dollars, not be discharged until the first business day following receipt by such
Underwriter or controlling person of any sum in such other currency, and only to the extent that such Underwriter or controlling person
may in accordance with normal banking procedures purchase United States dollars with such other currency. If the United States dollars
so purchased are less than the sum originally due to such Underwriter or controlling person hereunder, the Company and each Selling Shareholder
agrees as a separate obligation and notwithstanding any such judgment, to indemnify such Underwriter or controlling person against such
loss. If the United States dollars so purchased are greater than the sum originally due to such Underwriter or controlling person hereunder,
such Underwriter or controlling person agrees to pay to the Company or Selling Shareholder, as applicable, an amount equal to the excess
of the dollars so purchased over the sum originally due to such Underwriter or controlling person hereunder.
23. Representatives.
The Representatives will act for the several Underwriters in connection with the transactions contemplated by this Agreement, and
any action under this Agreement taken by the Representatives jointly will be binding upon all the Underwriters.
24. Recognition
of the U.S. Special Resolution Regimes. In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under
this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.
In the event that any Underwriter that is a Covered
Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights
under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default
Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or
a state of the United States.
For purposes of this Section 24: (A) a
“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted
in accordance with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered
entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered
bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered
FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right”
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as
applicable; and (D) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act
and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and
the regulations promulgated thereunder.
| |
Very truly yours, |
| |
|
| |
Atour Lifestyle Holdings Limited |
| |
|
| |
By: |
/s/ Haijun Wang |
| |
|
Name: |
Haijun Wang |
| |
|
Title: |
Chief Executive Officer and Chairman of the Board of Directors |
[Signature
page to Underwriting Agreement]
| |
Shanghai Yi Nan Enterprise Management Partnership |
| |
|
| |
By: |
/s/ Zhou Hongbin |
| |
|
Name: |
Zhou Hongbin |
| |
|
Title: |
Authorized Signatory |
| |
Shanghai Yin Nai Enterprise Management
Partnership |
| |
|
|
| |
By: |
/s/ Zhou Hongbin |
| |
|
Name: |
Zhou Hongbin |
| |
|
Title: |
Authorized Signatory |
[Signature
page to Underwriting Agreement]
Accepted as of the date hereof
BofA Securities, Inc.
| By: |
/s/ Shelton Tsui |
|
| |
Name: |
Shelton Tsui |
|
| |
Title: |
Director |
|
CMB International Capital Limited
| By: |
/s/ Alicia Zhang |
|
| |
Name: |
Alicia Zhang |
|
| |
Title: |
Managing Director |
|
| By: |
/s/ Crystal Lin |
|
| |
Name: |
Crystal Lin |
|
| |
Title: |
Executive Director |
|
| By: |
/s/ Alice Wang |
|
| |
Name: |
Alice Wang |
|
| |
Title: |
Vice President |
|
Citigroup Global Markets Inc.
| By: |
/s/ Xinyu Liu |
|
| |
Name: |
Xinyu Liu |
|
| |
Title: |
Managing Director |
|
[Signature page to Underwriting
Agreement]
SCHEDULE I
| Underwriters | |
Number of Firm ADSs
To Be Purchased | |
| BofA Securities, Inc. | |
| 6,500,000 | |
| CMB International Capital Limited | |
| 2,000,000 | |
| Citigroup Global Markets Inc. | |
| 1,500,000 | |
| Total: | |
| 10,000,000 | |
SCHEDULE II
| Selling Shareholders | |
Number of Firm
ADSs to be
Sold
| |
| Shanghai Yi Nan Enterprise Management Partnership | |
| 8,646,292 | |
| Shanghai Yin Nai Enterprise Management Partnership | |
| 1,353,708 | |
| Total: | |
| 10,000,000 | |
SCHEDULE III
Time of Sale Prospectus
| 1. | Preliminary Prospectus issued on June 10, 2024 |
| 2. | Pricing information: US$16.90 per ADS |
| 3. | ADSs offered: 10,000,000 ADSs (or 11,500,000 ADSs if the Underwriters
exercise the option to purchase Additional ADSs in full) |
SCHEDULE IV
Written Testing-the-Waters Communications
All written communications presented to potential
investors in reliance on Section 5(d) of the U.S. Securities Act of 1933, as amended, and submitted to the U.S. Securities and
Exchange Commission.
SCHEDULE V
Subsidiaries
EXHIBIT A
FORM OF LOCK-UP LETTER
____________, 20__
BofA Securities, Inc.
One Bryant Park
New York, NY 10036
United States of America
CMB International Capital Limited
45/F, Champion Tower
3 Garden Road
Central
Hong Kong
Citigroup Global Markets Inc.
388 Greenwich Street
New York, NY 10013
United States of America
Ladies and Gentlemen:
The undersigned understands that BofA Securities, Inc.,
CMB International Capital Limited and Citigroup Global Markets Inc. (the “Representatives”) propose to enter into
an Underwriting Agreement (the “Underwriting Agreement”) with Atour Lifestyle Holdings Limited, an exempted company
incorporated in the Cayman Islands (the “Company”) and certain shareholders thereof, providing for the public offering
(the “Public Offering”) by the several Underwriters, including the Representatives (the “Underwriters”),
of American Depositary Shares (“ADSs”) representing ordinary shares, par value US$0.0001 per share, of the Company
(the “Ordinary Shares”).
To
induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering,
the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, it will not
during the period commencing on the date hereof and ending 90 days after the date of the final prospectus (the “Restricted Period)”
relating to the Public Offering (the “Prospectus”), (1) offer, pledge, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer
or dispose of, directly or indirectly, any ADSs or Ordinary Shares beneficially owned (as such term is used in Rule 13d-3 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”)), by the undersigned or any other securities so owned
convertible into or exercisable or exchangeable for ADSs or Ordinary Shares or (2) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of ADSs or Ordinary Shares, whether any such
transaction described in clause (1) or (2) above is to be settled by delivery of ADSs, Ordinary Shares or such other securities,
in cash or otherwise. The foregoing sentence shall not apply to (a) transactions relating to ADSs, Ordinary Shares or other securities
acquired in open market transactions after the completion of the Public Offering, provided that no filing under the Exchange Act
or other public announcement shall be required or shall be voluntarily made in connection with subsequent sales of ADSs, Ordinary Shares
or other securities acquired in such open market transactions; (b) transfers of ADSs, Ordinary Shares or any security convertible
into ADSs or Ordinary Shares as a bona fide gift; (c) transfers of ADSs, Ordinary Shares or any security convertible into ADSs or
Ordinary Shares through will or intestacy, to immediate family members, to any trust for the direct or indirect benefit of the undersigned
or his or her immediate family members, or to any entity beneficially owned and controlled by the undersigned (or if the undersigned is
a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust; for purposes of this letter, “immediate
family” shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than
first cousin); (d) transfers of ADSs or Ordinary Shares or any security convertible into ADSs or Ordinary Shares by operation of
law, including pursuant to an order of a court or regulatory agency; (e) if the undersigned is a corporation, partnership, limited
liability company, trust or other business entity, distributions of ADSs or Ordinary Shares or any security convertible into ADSs or Ordinary
Shares to limited partners or shareholders of the undersigned; provided that in the case of
any transfer or distribution pursuant to clause (b) through (e), (i) each donee, transferee or distributee shall sign and
deliver a lock-up letter substantially in the form of this letter and (ii) no filing under the Exchange Act or other public announcement,
reporting a reduction in beneficial ownership of ADSs or Ordinary Shares, shall be required or shall be voluntarily made during the Restricted
Period, and (iii) any such transfer or distribution shall not involve a disposition for value; (f) the exercise of the undersigned’s
rights to acquire ADSs or Ordinary Shares upon the exercise of options that were granted pursuant to an agreement or equity awards granted
under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the Prospectus, provided
that any such Ordinary Shares received upon such exercise shall be subject to the terms of this letter; (g) the transfer of ADSs
or Ordinary Shares to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants
or other rights to purchase shares of Ordinary Shares (including, in each case, by way of “net” or “cashless”
exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or
exercise of such restricted stock units, options, warrants or rights, provided that any such Ordinary Shares received upon such
exercise, vesting or settlement shall be subject to the terms of this letter, and provided further that any such restricted stock units,
options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan
or other equity award plan which is described in the Prospectus; or (h) the establishment of a trading plan pursuant to Rule 10b5-1
under the Exchange Act for the transfer of ADSs or Ordinary Shares, provided that (i) such plan does not provide for the transfer
of ADSs or Ordinary Shares during the Restricted Period and (ii) no public announcement or filing under the Exchange Act is required
of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan. In addition, the undersigned
agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, it will not, during the Restricted
Period, make any demand for or exercise any right with respect to, the registration of any shares of ADSs or Ordinary Shares or any security
convertible into or exercisable or exchangeable for ADSs or Ordinary Shares. The undersigned also agrees and consents to the entry of
stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s ADSs
or Ordinary Shares except in compliance with the foregoing restrictions.
The undersigned understands that the Company and
the Underwriters are relying upon this letter in proceeding toward consummation of the Public Offering. The undersigned further understands
that this letter is irrevocable and shall be binding upon the undersigned’s, heirs, legal representatives, successors and assigns.
The undersigned hereby submits to the exclusive
jurisdiction of any New York State or United States Federal court sitting in Borough of Manhattan in The City of New York over any suit,
action or proceeding arising out of or relating to this letter (each, a “Related Proceeding”). The undersigned irrevocably
waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any Related
Proceeding brought in such a court and any claim that any such Related Proceeding brought in such a court has been brought in an inconvenient
forum.
Whether or not the Public Offering actually occurs
depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Underwriters.
This letter agreement shall automatically terminate
and be of no further force and effect on the earlier of (i) the date that the Company advises the Representatives in writing, prior
to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii) subsequent to
signing the Underwriting Agreement, the Underwriting Agreement (other than the provisions thereof which survive termination) is terminated
prior to payment for and delivery of the ADSs to be sold thereunder, (iii) September 30, 2024 if the Public Offering has not
been completed by or before such date, (iv) the expiration of the Restricted Period, or (v) the withdrawal of the registration
statement filed with the U.S. Securities and Exchange Commission with respect to the Public Offering.
This letter shall be governed by and construed
in accordance with the laws of the State of New York.
| |
Very truly yours, |
| |
|
| |
|
| |
(Name) |
| |
|
| |
|
| |
(Address) |
Exhibit 5.1
| Our
ref | SQG/675005-000001/29581996v2 |
ATOUR LIFESTYLE HOLDINGS LIMITED
18th floor, Wuzhong Building,
618 Wuzhong Road, Minhang District,
Shanghai, People’s Republic of China
12 June 2024
Dear Sirs
ATOUR LIFESTYLE HOLDINGS LIMITED
We
have acted as Cayman Islands legal advisers to ATOUR LIFESTYLE HOLDINGS LIMITED (the "Company") in connection with the
Company’s registration statement on Form F-3, including all amendments or supplements thereto (the "Registration Statement"),
filed with the Securities and Exchange Commission (the “Commission”) on 4 December 2023 under the U.S. Securities
Act of 1933, as amended to date, and the base prospectus included therein, the preliminary prospectus supplement dated 10 June 2024 and
the final prospectus supplement dated 11 June 2024 (collectively, the “Prospectus”) relating to the resale by Shanghai
Yi Nan Enterprise Management Partnership and Shanghai Yin Nai Enterprise Management Partnership (collectively, the “Selling
Shareholders”) of the Company's 11,500,000 American depositary shares (the "ADSs"), representing 34,500,000
Class A ordinary shares of par value US$0.0001 each of the Company (the "Shares"). The Shares include 4,500,000
Class A ordinary shares of the Company to be purchased pursuant to the option granted to the underwriters by the Selling Shareholders.
We are furnishing this opinion as Exhibits 5.1
to the Registration Statement.
For the purposes of this opinion, we have reviewed
only originals, copies or final drafts of the following documents:
| 1.1 | The certificate of incorporation of the Company dated 20 April 2012 and the certificate of incorporation
on change of name of the Company dated 16 June 2015 issued by the Registrar of Companies in the Cayman Islands. |
| 1.2 | The ninth amended and restated memorandum and articles of association of the Company as conditionally
adopted by a special resolution passed on 2 September 2021 and effective immediately prior to the completion of the Company’s
initial public offering of ADSs representing its Class A Ordinary Shares (the "Memorandum and Articles"). |
| 1.3 | The written resolutions of the board of directors of the Company dated 7 June 2024 (the
"Board Resolutions"). |
| 1.4 | A certificate from a director of the Company, a copy of which is attached hereto (the "Director's
Certificate"). |
| 1.5 | A certificate of good standing dated 31 May 2024, issued by the Registrar of Companies in the Cayman
Islands (the "Certificate of Good Standing"). |
| 1.6 | The Registration Statement. |
The following opinions are given only as to, and
based on, circumstances and matters of fact existing and known to us on the date of this opinion letter. These opinions only relate to
the laws of the Cayman Islands which are in force on the date of this opinion letter. In giving these opinions we have relied (without
further verification) upon the completeness and accuracy, as of the date of this opinion letter, of the Director's Certificate and the
Certificate of Good Standing. We have also relied upon the following assumptions, which we have not independently verified:
| 2.1 | Copies of documents, conformed copies or drafts of documents provided to us are true and complete copies
of, or in the final forms of, the originals. |
| 2.2 | All signatures, initials and seals are genuine. |
| 2.3 | There is nothing contained in the minute book or corporate records of the Company (which we have not inspected)
which would or might affect the opinions set out below. |
| 2.4 | There is nothing under any law (other than the law of the Cayman Islands), which would or might affect
the opinions set out below. |
Based upon the foregoing and subject to the qualifications set out
below and having regard to such legal considerations as we deem relevant, we are of the opinion that:
| 3.1 | The Company has been duly incorporated as an exempted company with limited liability and is validly existing
and in good standing with the Registrar of Companies under the laws of the Cayman Islands. |
| 3.2 | The authorised share capital of the Company is US$300,000 divided into 3,000,000,000 ordinary shares of
par value of US$0.0001 each, comprising (a) 2,900,000,000 Class A Ordinary Shares of par value of US$0.0001 each, and (b) 100,000,000
Class B Ordinary Shares of par value of US$0.0001 each. |
| 3.3 | The sale and transfer of the Shares as contemplated by the Registration Statement and the Prospectus by
the Selling Shareholders have been duly authorised by or on behalf of the Company. |
| 3.4 | The statements under the caption "Cayman Islands Taxation" in the prospectus forming part of
the Registration Statement, to the extent that they constitute statements of Cayman Islands law, are accurate in all material respects
and that such statements constitute our opinion. |
Except as specifically stated herein, we make
no comment with respect to any representations and warranties which may be made by or with respect to the Company in any of the documents
or instruments cited in this opinion or otherwise with respect to the commercial terms of the transactions, which are the subject of this
opinion.
We hereby consent to the filing of this opinion
as an exhibit to the Registration Statement and to the reference to our name under the headings "Enforceability of Civil Liabilities",
"Taxation" and "Legal Matters" and elsewhere in the prospectus included in the Registration Statement. In giving such
consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the U.S.
Securities Act of 1933, as amended, or the Rules and Regulations of the Commission thereunder.
Yours faithfully
/s/ Maples and Calder (Hong Kong) LLP
Maples and Calder (Hong Kong) LLP
Atour Lifestyle (NASDAQ:ATAT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Atour Lifestyle (NASDAQ:ATAT)
Historical Stock Chart
From Dec 2023 to Dec 2024
